CareDx, Inc.CDNAEarnings & Financial Report
CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.
CDNA Q1 FY2026 Key Financial Metrics
Revenue
$117.7M
Gross Profit
N/A
Operating Profit
$1.2M
Net Profit
$2.8M
Gross Margin
N/A
Operating Margin
1.0%
Net Margin
2.4%
YoY Growth
39.0%
EPS
$0.05
CareDx, Inc. Q1 FY2026 Financial Summary
CareDx, Inc. reported revenue of $117.7M (up 39.0% YoY) for Q1 FY2026, with a net profit of $2.8M (2.4% margin).
Key Financial Metrics
| Total Revenue | $117.7M |
|---|---|
| Net Profit | $2.8M |
| Gross Margin | N/A |
| Operating Margin | 1.0% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
CareDx, Inc. Q1 FY2026 revenue of $117.7M breaks down across 4 segments, led by Financial Results Total at $85.0M (72.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Financial Results Total | $85.0M | 72.2% |
| Patient and digital solutions revenue | $16.0M | 13.6% |
| Product revenue | $10.3M | 8.8% |
| Other | $6.4M | 5.4% |
CareDx, Inc. Annual Revenue by Year
CareDx, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $379.8M).
CareDx, Inc. Quarterly Revenue & Net Profit History
CareDx, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $117.7M | +39.0% | $2.8M | 2.4% |
| Q4 FY2025 | $108.4M | +25.2% | $-4.1M | -3.8% |
| Q3 FY2025 | $100.1M | +20.7% | $1.7M | 1.7% |
| Q2 FY2025 | $86.7M | -6.1% | $-8.6M | -9.9% |
| Q1 FY2025 | $84.7M | +17.5% | $-10.4M | -12.2% |
| Q4 FY2024 | $86.6M | +32.0% | $87.7M | 101.3% |
| Q3 FY2024 | $82.9M | +23.4% | $-10.6M | -12.8% |
| Q2 FY2024 | $92.3M | +31.3% | $-4.6M | -5.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $92.3M | $82.9M | $86.6M | $84.7M | $86.7M | $100.1M | $108.4M | $117.7M |
| YoY Growth | 31.3% | 23.4% | 32.0% | 17.5% | -6.1% | 20.7% | 25.2% | 39.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $466.8M | $477.0M | $491.1M | $489.6M | $444.3M | $432.3M | $413.2M | $411.1M |
| Liabilities | $202.1M | $203.7M | $112.6M | $110.3M | $116.9M | $121.2M | $110.1M | $97.5M |
| Equity | $264.7M | $273.2M | $378.4M | $379.3M | $327.4M | $311.1M | $303.1M | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $18.9M | $12.5M | $21.9M | $-26.6M | $9.9M | $37.4M | $21.4M | $4.3M |